11 April 2024

IAMA Therapeutics Appoints Federico Bolognani as Chief Medical Officer

GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in […]
19 February 2024

IAMA Therapeutics Successfully Dosed the First Two Cohorts in First-in-Human Clinical Trial

GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]
23 January 2024

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
13 September 2023

IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum

GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
10 July 2023

IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy

GENOA, Italy, July 10, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]